ArticleFrontiers in public health2024

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.

Wenjie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.